Pictet Asset Management
BMRN icon

Pictet Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pictet Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.1M Sell
1,193,661
-89,961
-7% -$5.25M 0.07% 267
2025
Q4 		$76.4M Buy
1,283,622
+393,409
+44% +$21.4M 0.07% 255
2025
Q3 		$48.2M Sell
890,213
-203,165
-19% -$11.6M 0.05% 333
2025
Q2 		$60.1M Buy
1,093,378
+808,078
+283% +$47.6M 0.06% 293
2025
Q1 		$20.3M Buy
285,300
+600
+0.2% +$40.4K 0.02% 492
2024
Q4 		$18.7M Sell
284,700
-634,916
-69% -$42.5M 0.02% 522
2024
Q3 		$64.7M Sell
919,616
-743,547
-45% -$62.2M 0.07% 253
2024
Q2 		$137M Sell
1,663,163
-242,446
-13% -$20.2M 0.16% 159
2024
Q1 		$167M Buy
1,905,609
+468,886
+33% +$42M 0.18% 147
2023
Q4 		$139M Sell
1,436,723
-505,522
-26% -$44.7M 0.15% 168
2023
Q3 		$172M Buy
+1,942,245
New +$173M 0.21% 131

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management's BMRN Position: Q1 2026 in Review

Pictet Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 7% in Q1 2026, selling an estimated $5.25M and leaving 1,193,661 shares worth $67.1M. The position accounts for 0.07% of the portfolio, ranked #267.

Pictet Asset Management first reported a position in BMRN in Q3 2023 and has held it in 11 quarters since. The position peaked at $172M in Q3 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Pictet Asset Management held 1,193,661 shares of BioMarin Pharmaceuticals worth $67.1M as of Q1 2026.
  • Pictet Asset Management sold 89,961 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.25M.
  • BioMarin Pharmaceuticals made up 0.07% of Pictet Asset Management's portfolio in Q1 2026, its #267 holding.
  • Pictet Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's BioMarin Pharmaceuticals position peaked at $172M in Q3 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.